CNMD

It has been about a month since the last earnings report for Henry Schein (HSIC). Shares have added about 0.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Henry Schein due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important catalysts. Henry Schein, Inc. reported second-quarter 2026 adjusted earnings of $1.27 per share, up 15.5% year over year. The bottom line surpassed the Zacks Consensus Estimate by 4.1%. Net sales rose 6.7% to $3.46 billion and beat the consensus estimate by 2.8%. Results benefited from 4.6% internal sales growth, with gains across distribution, specialty products and technology. Acquisitions contributed 0.7% to growth, while foreign currency movements added 1.4%. Henry Schein’s Distribution Business Gains Global Distribution and Value-Added Services sales increased 6.6% to $2.91 billion. The segment generated 4.5% internal growth, a 0.6% contribution from acquisitions and a 1.5% foreign exchange benefit. Global Medical Distribution sales advanced 4% to $1.06 billion, supported by 3.9% internal growth. Global Value-Added Services sales increased 5.1% to $61 million, reflecting 3.7% internal growth. U.S. Distribution and Value-Added Services sales rose 4.6% to $1.95 billion. International sales in the segment climbed 10.7% to $965 million, aided by 5.5% internal growth and a 4.5% currency benefit. HSIC’s Specialty and Technology Sales Rise Global Specialty Products sales increased 8.7% to $419 million. Internal growth was 3.2%, acquisitions contributed 3.4% and foreign currency exchange added 2.1%. Global Technology sales advanced 8.2% to $181 million. Internal sales grew 9.1%, partly offset by a 1.3% reduction related to a business disposal. Foreign exchange contributed 0.4%. Technology delivered the company’s highest internal growth rate among its major reporting categories. The performance complemented steady gains in dental merchandise, medical distribution and specialty products. HSIC’s Margin Performance In the reported quarter, gross profit totaled $1.10 billion, representing an 8.4% increase year over year. The gross margin expanded 48 basis points (bps) to 31.8% despite a 6% rise in the cost of sales. Selling, general and administrative expenses increased 6.8% to $831 million. Operating income rose 13.2% to $171 million, while the operating margin expanded 28 bps year over year to 4.9%. Liquidity Position of HSIC Henry Schein exited the second quarter of 2026 with cash and cash equivalents of $157 million compared with $138 million at March-end. Cumulative net cash provided by operating activities at the end of the reported quarter was $145 million compared with $157 million a year ago. Henry Schein Raises Its 2026 Outlook Management raised its 2026 adjusted earnings guidance to $5.29-$5.39 per share, from the earlier $5.23-$5.37 range. The Zacks Consensus Estimate for earnings currently stands at $5.32 per share. The company also lifted its total sales growth forecast to 4.5%-5.5% from 3%-5%. The Zacks Consensus Estimate for sales is currently pegged at $13.72 billion, indicating 4.1% year-over-year growth. Adjusted EBITDA is now expected to grow at a mid- to high-single-digit rate, compared with the prior expectation of mid-single-digit growth. Management cited sustained business momentum, margin improvement and early benefits from its value creation initiatives. The updated outlook assumes foreign exchange rates remain generally consistent with current levels. It excludes future tariff refunds, remeasurement gains and several items that management does not consider representative of underlying performance. It turns out, fresh estimates flatlined during the past month. At this time, Henry Schein has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a score of A on the value side, putting it in the top 20% for this investment strategy. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Henry Schein has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months. Henry Schein is part of the Zacks Medical - Dental Supplies industry. Over the past month, Conmed (CNMD), a stock from the same industry, has gained 0.3%. The company reported its results for the quarter ended June 2026 more than a month ago. Conmed reported revenues of $343.49 million in the last reported quarter, representing a year-over-year change of +0.3%. EPS of $1.38 for the same period compares with $1.15 a year ago. For the current quarter, Conmed is expected to post earnings of $1.00 per share, indicating a change of -7.4% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days. Conmed has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Henry Schein, Inc. (HSIC) : Free Stock Analysis Report CONMED Corporation (CNMD) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

A month has gone by since the last earnings report for Conmed (CNMD). Shares have added about 7.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Conmed due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for CONMED Corporation before we dive into how investors and analysts have reacted as of late. CONMEDposted adjusted earnings per share of $1.38 for the second quarter of 2026, up 20% year over year. The figure beat the Zacks Consensus Estimate by 25.5%. The adjustments include costs related to legal matters and contingent consideration fair value adjustments, among others. GAAP EPS for the quarter was 77 cents, up 11.6% from the year-ago period’s EPS of 69 cents. CNMD’s second-quarter revenues of $343.5 million increased 0.3% year over year and beat the consensus estimate by 1.9%. International strength and growth across the company’s key AirSeal, Buffalo Filter and BioBrace platforms supported the quarter. At constant currency, total revenues declined 0.5% year over year. However, excluding sales tied to CONMED’s strategic exit from certain gastroenterology product offerings, organic constant-currency revenues increased 6%. Domestic sales totaled $175.4 million, down 8% on a reported basis. Excluding the GI exits, domestic organic revenues rose 2.5%. International sales reached $168.1 million, up 10.8% on a reported basis and 8.9% at constant currency. International organic constant-currency growth was 9.9%. Orthopedic Surgery revenues totaled $152.3 million, up 8.2% year over year on a reported basis and 6.8% at constant currency. International orthopedic revenues advanced 10.8% at constant exchange rates, reflecting broad-based growth across major regions. Domestic orthopedic sales were nearly flat and fell short of management’s expectations. Nonetheless, the company continued to strengthen its U.S. commercial organization. BioBrace was a major contributor, supported by adoption across orthopedic and foot-and-ankle procedures, particularly rotator cuff repair. General Surgery revenues were $191.2 million, down 5.2% on a reported basis and 5.6% at constant currency. The decline reflected the impact of the GI portfolio exits. On an organic constant-currency basis, General Surgery sales increased 5.3%. AirSeal and Buffalo Filter led the underlying growth. AirSeal sales increased across capital and single-use products and improved sequentially, but growth remained below management’s expectations. CONMED expects AirSeal trends to improve during the second half of 2026, but at a slower rate than previously assumed. Direct smoke evacuation sales exceeded the company’s long-term expectation of high-single-digit to low-double-digit growth. This more than offset a modest decline in original equipment manufacturer smoke evacuation sales. The company continues to prioritize its direct Buffalo Filter portfolio, which carries a stronger margin profile and brings CONMED closer to customers. Management also highlighted early commercial traction in Europe, Canada and Australia, along with expanding U.S. legislation requiring surgical smoke evacuation systems. In the quarter under review, CNMD’s adjusted gross profit increased 5.6% year over year to $204.4 million. The adjusted gross margin expanded 300 basis points (bps) to 59.5%. The improvement included an $8.5 million benefit from tariff refunds, which contributed nearly 250 bps to the year-over-year expansion. In the quarter under review, CNMD’s reported gross profit increased 4.9% year over year to $197.5 million. The gross margin expanded 250 bps to 57.5%. Selling & administrative expenses increased 7% year over year to $145.6 million. Research and development expenses rose 9.6% year over year to $15.5 million. Total operating expenses of $161.1 million increased 7.3% on a year-over-year basis. Total operating profit totaled $36.4 million, reflecting a 4.6% decrease from the year-ago quarter. The operating margin contracted 50 bps to 10.6%. The company exited the second quarter with cash and cash equivalents of $37.3 million compared with $35 million a year ago. Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $50.6 million compared with $70.7 million a year ago. CNMD has updated its outlook for 2026. For 2026, total reported revenues are expected to be in the range of $1,358 million-$1,373 million compared with the previous guidance of $1,350 million-$1,375 million. This represents a reported revenue decline of 1.2-0.1% year over year. Organic constant-currency revenue growth is expected to be 5-6% compared with the prior projection of 5-6.5%. The revised outlook reflects second-quarter performance and a more measured pace of sequential growth improvement in the second half of 2026. The company now expects adjustedearnings per share PS for 2026 in the range of $4.48-$4.60, up from its previous guidance of $4.30-$4.45. The raised outlook reflects better-than-expected second-quarter results, a lower projected headwind from the GI product exits and a higher contribution from share repurchases. These benefits are expected to be partly offset by higher interest expenses and an increased tax-rate assumption. CONMED expects third-quarter revenues to be in the range of $334 million-$339 million. Organic constant-currency growth is projected to be between 6.4% and 7.6%, excluding anticipated GI revenues of $3 million-$3.6 million and an approximately 10-basis-point foreign currency impact. Adjusted earnings per share is expected to be between 98 cents and $1.03. It turns out, estimates review have trended downward during the past month. Currently, Conmed has a average Growth Score of C, however its Momentum Score is doing a bit better with a B. Charting a somewhat similar path, the stock was allocated a grade of A on the value side, putting it in the top 20% for value investors. Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Conmed has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CONMED Corporation (CNMD) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

CONMED Corporation CNMD posted adjusted earnings per share (EPS) of $1.38 for the second quarter of 2026, up 20% year over year. The figure beat the Zacks Consensus Estimate by 25.5%. The adjustments include costs related to legal matters and contingent consideration fair value adjustments, among others. GAAP EPS for the quarter was 77 cents, up 11.6% from the year-ago period’s EPS of 69 cents. CNMD’s second-quarter revenues of $343.5 million increased 0.3% year over year and beat the consensus estimate by 1.9%. International strength and growth across the company’s key AirSeal, Buffalo Filter and BioBrace platforms supported the quarter. Shares of CNMD gained 6.3 in today’s pre-market trading. In the year-to-date period, shares of the company gained 6.4% compared with the industry’s 3.3% growth. The S&P 500 increased 8.1% in the same time frame. At constant currency, total revenues declined 0.5% year over year. However, excluding sales tied to CONMED’s strategic exit from certain gastroenterology product offerings, organic constant-currency revenues increased 6%. Domestic sales totaled $175.4 million, down 8% on a reported basis. Excluding the GI exits, domestic organic revenues rose 2.5%. International sales reached $168.1 million, up 10.8% on a reported basis and 8.9% at constant currency. International organic constant-currency growth was 9.9%. Image Source: Zacks Investment Research Orthopedic Surgery revenues totaled $152.3 million, up 8.2% year over year on a reported basis and 6.8% at constant currency. International orthopedic revenues advanced 10.8% at constant exchange rates, reflecting broad-based growth across major regions. Domestic orthopedic sales were nearly flat and fell short of management’s expectations. Nonetheless, the company continued to strengthen its U.S. commercial organization. BioBrace was a major contributor, supported by adoption across orthopedic and foot-and-ankle procedures, particularly rotator cuff repair. General Surgery revenues were $191.2 million, down 5.2% on a reported basis and 5.6% at constant currency. The decline reflected the impact of the GI portfolio exits. On an organic constant-currency basis, General Surgery sales increased 5.3%. AirSeal and Buffalo Filter led the underlying growth. AirSeal sales increased across capital and single-use products and improved sequentially, but growth remained below management’s expectations. CONMED expects AirSeal trends to improve during the second half of 2026, but at a slower rate than previously assumed. Direct smoke evacuation sales exceeded the company’s long-term expectation of high-single-digit to low-double-digit growth. This more than offset a modest decline in original equipment manufacturer smoke evacuation sales. The company continues to prioritize its direct Buffalo Filter portfolio, which carries a stronger margin profile and brings CONMED closer to customers. Management also highlighted early commercial traction in Europe, Canada and Australia, along with expanding U.S. legislation requiring surgical smoke evacuation systems. In the quarter under review, CNMD’s adjusted gross profit increased 5.6% year over year to $204.4 million. The adjusted gross margin expanded 300 basis points (bps) to 59.5%. The improvement included an $8.5 million benefit from tariff refunds, which contributed nearly 250 bps to the year-over-year expansion. In the quarter under review, CNMD’s reported gross profit increased 4.9% year over year to $197.5 million. The gross margin expanded 250 bps to 57.5%. Selling & administrative expenses increased 7% year over year to $145.6 million. Research and development expenses rose 9.6% year over year to $15.5 million. Total operating expenses of $161.1 million increased 7.3% on a year-over-year basis. Total operating profit totaled $36.4 million, reflecting a 4.6% decrease from the year-ago quarter. The operating margin contracted 50 bps to 10.6%. CONMED Corporation price-consensus-eps-surprise-chart | CONMED Corporation Quote The company exited the second quarter with cash and cash equivalents of $37.3 million compared with $35 million a year ago. Cumulative net cash provided by operating activities at the end of second-quarter 2026 was $50.6 million compared with $70.7 million a year ago. CNMD has updated its outlook for 2026. For 2026, total reported revenues are expected to be in the range of $1,358 million-$1,373 million compared with the previous guidance of $1,350 million-$1,375 million. This represents a reported revenue decline of 1.2-0.1% year over year. Organic constant-currency revenue growth is expected to be 5-6% compared with the prior projection of 5-6.5%. The revised outlook reflects second-quarter performance and a more measured pace of sequential growth improvement in the second half of 2026. The company now expects adjusted EPS for 2026 in the range of $4.48-$4.60, up from its previous guidance of $4.30-$4.45. The raised outlook reflects better-than-expected second-quarter results, a lower projected headwind from the GI product exits and a higher contribution from share repurchases. These benefits are expected to be partly offset by higher interest expenses and an increased tax-rate assumption. CONMED expects third-quarter revenues to be in the range of $334 million-$339 million. Organic constant-currency growth is projected to be between 6.4% and 7.6%, excluding anticipated GI revenues of $3 million-$3.6 million and an approximately 10-basis-point foreign currency impact. Adjusted EPS is expected to be between 98 cents and $1.03. CONMED exited the second quarter of 2026 with better-than-expected earnings and revenues. Organic constant-currency sales growth of 6% reflected gains across both Orthopedic Surgery and General Surgery, supported by continued momentum in AirSeal, Buffalo Filter and BioBrace. The completion of the GI portfolio exit should allow the company to sharpen its focus on these core growth platforms. AirSeal continues to benefit from opportunities in robotic and laparoscopic procedures, although second-quarter growth was below management’s expectations. Buffalo Filter remains well positioned to gain from expanding smoke-evacuation legislation and international adoption, while BioBrace continues to see traction in rotator cuff repair and other orthopedic procedures. Improved supply-chain execution, including lower backorders and stronger service levels, should also support more consistent operating performance. However, challenges remain. The GI exit continues to weigh on reported revenues, while AirSeal’s growth outlook for the second half is lower than previously assumed. Domestic orthopedic sales were nearly flat, and modest weakness in the OEM smoke-evacuation business also pressured General Surgery. Moreover, higher interest expenses following the debt refinancing may limit earnings growth. Despite these headwinds, CONMED raised its adjusted earnings outlook for 2026 and continues to expect organic constant-currency growth of 5-6%. CNMD currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the broader medical space are McKesson MCK, Phibro Animal Health PAHC andCardinal Health CAH. McKesson carries a Zacks Rank #2 (Buy) at present and has an estimated long-term growth rate of 13.7%. MCK’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.09%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. McKesson shares have gained 8.8% against the industry’s 12.7% decline in the year-to-date period. Phibro Animal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.5%. PAHC’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 16.25%. Phibro Animal Health stock has climbed 44.2% against the industry’s 17.1% decline in the year-to-date period. Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 17%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. Cardinal Health’s shares have lost 2.6% compared with the industry’s 3.1% decline in the year-to-date period. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CONMED Corporation (CNMD) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report McKesson Corporation (MCK) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Interested in CONMED Corporation? Here are five stocks we like better. CONMED delivered better-than-expected Q2 results: Organic sales rose 6%, adjusted EPS increased 20% to $1.38, and free cash flow grew 46% to $34.2 million. Results benefited from a $0.21-per-share tariff refund, though earnings still exceeded the high end of prior guidance without it. Growth was led by general surgery products AirSeal and Buffalo Filter and international orthopedics, including BioBrace. AirSeal growth came in below expectations, while U.S. orthopedic sales were essentially flat as the company reorganized its commercial team. CONMED raised its 2026 adjusted EPS outlook to $4.48–$4.60 but narrowed organic sales-growth guidance to 5%–6% and lowered free-cash-flow expectations to about $115 million. The company also refinanced and repurchased $645.2 million of convertible notes due in 2027. Med-tech stock Conmed dips ahead of big Q4 report...opportunity? CONMED (NYSE:CNMD) reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company’s exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management’s expectations. Adjusted diluted earnings per share increased 20% year over year to $1.38, compared with $1.15 in the prior-year period. The result included a $0.21-per-share benefit from tariff refunds that had not been included in the company’s guidance. Excluding that benefit, earnings still exceeded the high end of CONMED’s prior guidance by about $0.03 per share, President and CEO Pat Beyer said. → This Tiny AI Supplier Could Be More Important Than the Chipmakers “We were pleased to deliver strong financial performance in the second quarter,” Beyer said, pointing to organic growth in both the general surgery and orthopedic surgery businesses. General surgery organic sales increased 5.3%, with mid-single-digit growth in the U.S. and high-single-digit international growth. AirSeal, CONMED’s advanced insufflation platform, and Buffalo Filter, its smoke-evacuation platform, were the principal contributors. → Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There? AirSeal sales grew in both capital equipment and single-use products, and trends improved sequentially from the first quarter. However, Beyer said growth was below the company’s expectations. CONMED now expects AirSeal growth to improve in the second half of 2026, though at a slower pace than previously assumed in guidance. The company maintained its long-term view that AirSeal can grow at a high-single-digit to low-double-digit rate, citing its use in robotic and laparoscopic procedures as well as expansion opportunities in ambulatory surgery centers, international markets and U.S. laparoscopy. CONMED estimates AirSeal is used in only 6% to 7% of more than 3 million laparoscopic procedures performed annually in the United States. → Innovative ETF Strategies That Are Paying Off This Summer CONMED also announced that its AirSeal Robotic Solution is now indicated for use with Intuitive’s 8mm hex cannulas, in addition to the existing indication for 8mm round cannulas. The hex cannulas were introduced with the da Vinci 5 system and are compatible across Intuitive’s X, Xi and da Vinci 5 multi-port platforms. Beyer said the expanded indication was already incorporated into the company’s outlook. Buffalo Filter’s direct smoke-evacuation portfolio delivered year-over-year growth above the company’s long-term expectation of high-single-digit to low-double-digit growth, more than offsetting modest declines in its OEM smoke-evacuation business. CONMED said it is prioritizing direct sales because of closer customer relationships and a stronger margin profile. The company cited legislative support for surgical smoke evacuation, including recently enacted laws in Michigan and Maryland. CONMED said 22 states now have smoke-free operating-room laws, covering about 57% of the U.S. population, while more than 10 additional states have pending legislation. Orthopedic surgery sales increased 6.8%, driven by 10.8% international growth, including particular strength in Asia-Pacific and Europe, the Middle East and Africa. U.S. orthopedic sales were essentially flat and below expectations. Beyer said the domestic orthopedic business had undertaken strategic actions to strengthen its commercial organization during the quarter, which temporarily affected growth. He said the U.S. team is “back on offense” and positioned to return to growth. BioBrace, CONMED’s reinforced bioinductive implant, was a leading contributor to orthopedic growth. The product is being used across orthopedic and foot-and-ankle procedures, particularly rotator cuff repairs. Beyer cited CONMED’s clinical data and updated American Academy of Orthopaedic Surgeons guidelines supporting augmentation in rotator cuff repair as factors supporting adoption. The company said BioBrace RC, launched one year ago to streamline use of the implant in rotator cuff procedures, has generated increasing new-user adoption and repeat use among surgeons. Adjusted gross profit rose 5.6%, while adjusted gross margin expanded 300 basis points to 59.5%. The tariff refund accounted for approximately 250 basis points of margin improvement. Excluding the refund, adjusted gross margin increased 50 basis points, aided by product mix and foreign currency. Adjusted operating margin was 18.2%, compared with 15.7% a year earlier. Adjusted net income was $41.7 million, compared with $35.6 million in the prior-year quarter. Free cash flow rose 46% to $34.2 million. Cash totaled $37.3 million at June 30, while total debt obligations were $834.2 million. CONMED’s leverage ratio was 2.9 times at quarter-end. During June, CONMED secured a new $450 million senior secured term loan facility maturing in 2030. It used the proceeds, along with borrowings under its revolving credit facility, to repurchase $645.2 million of convertible notes for $637.2 million. The notes had been scheduled to mature in June 2027. The company also repurchased about 1 million shares for $43.7 million during the first half and continues to expect approximately $61.8 million in full-year share repurchases. CONMED narrowed its expected organic constant-currency sales growth range to 5% to 6%, from 5% to 6.5%. Beyer said the company reaffirmed confidence in achieving at least 5% growth, but adopted a more measured expectation for improvement in the second half because of the AirSeal outlook. The company raised its full-year adjusted EPS forecast to $4.48 to $4.60 from $4.30 to $4.45. CFO John Gallagher said the increase reflected the tariff refund, better-than-expected second-quarter operations, a smaller expected headwind from the GI exit and share repurchases. Those factors were partly offset by higher expected interest expense and a higher tax-rate assumption. CONMED now expects adjusted interest expense of about $33 million for 2026, compared with its earlier forecast of $25 million to $27 million. It reduced its free-cash-flow outlook to approximately $115 million from approximately $125 million, primarily due to working capital, interest expense and tax-rate changes. For the third quarter, CONMED forecast GAAP net sales of $334 million to $339 million, organic constant-currency growth of 6.4% to 7.6%, and adjusted EPS of $0.98 to $1.03. CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company's product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology. CONMED operates two principal segments: Orthopedics, and Visualization & Energy. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "CONMED Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for July 2026.

For the quarter ended June 2026, Conmed (CNMD) reported revenue of $343.49 million, up 0.3% over the same period last year. EPS came in at $1.38, compared to $1.15 in the year-ago quarter. The reported revenue represents a surprise of +1.85% over the Zacks Consensus Estimate of $337.24 million. With the consensus EPS estimate being $1.10, the EPS surprise was +25.46%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Conmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenue- International: $168.1 million versus $153.69 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change. Geographic Revenue- Domestic: $175.4 million compared to the $183.55 million average estimate based on two analysts. The reported number represents a change of -8% year over year. Net Sales- Single-use Products: $295.1 million versus the two-analyst average estimate of $286.83 million. The reported number represents a year-over-year change of -0.9%. Net Sales- General Surgery: $191.2 million compared to the $186.32 million average estimate based on two analysts. The reported number represents a change of -5.2% year over year. Net Sales- Orthopedic Surgery: $152.3 million versus the two-analyst average estimate of $150.93 million. The reported number represents a year-over-year change of +8.2%. Net Sales- Capital Products: $48.4 million versus the two-analyst average estimate of $50.42 million. The reported number represents a year-over-year change of +8.8%. View all Key Company Metrics for Conmed here>>> Shares of Conmed have returned +35.2% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CONMED Corporation (CNMD) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Conmed (CNMD) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.1 per share. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +25.46%. A quarter ago, it was expected that this medical technology company would post earnings of $0.82 per share when it actually produced earnings of $0.89, delivering a surprise of +8.54%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Conmed, which belongs to the Zacks Medical - Dental Supplies industry, posted revenues of $343.49 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.85%. This compares to year-ago revenues of $342.35 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Conmed shares have added about 9% since the beginning of the year versus the S&P 500's gain of 8.5%. While Conmed has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Conmed was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.05 on $334.99 million in revenues for the coming quarter and $4.38 on $1.36 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Dental Supplies is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Dentsply International (XRAY), another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6. This dental products manufacturer is expected to post quarterly earnings of $0.36 per share in its upcoming report, which represents a year-over-year change of -30.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Dentsply International's revenues are expected to be $883.85 million, down 5.6% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CONMED Corporation (CNMD) : Free Stock Analysis Report DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

LARGO, Fla., July 29, 2026--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026. Second Quarter 2026 Highlights(1) Sales of $343.5 million increased 0.3% year-over-year as reported and decreased 0.5% on a constant currency(2) basis. Diluted earnings per share (GAAP) were $0.77, up 11.6%. Adjusted diluted earnings per share(2) were $1.38, up 20.0%. Second Quarter 2026 and Recent Operational Announcements On May 20, 2026, the Company announced the appointment of Celine Martin and Jeff Mirviss to the Board of Directors, effective July 1, 2026. On June 17, 2026, the Company announced the appointment of John E. Gallagher as Chief Financial Officer, effective July 15, 2026. On July 22, 2026, the Company announced the AirSeal® Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform. "We delivered a strong second quarter, with organic constant currency net sales growth and adjusted diluted EPS that exceeded our stated expectations," said Patrick J. Beyer, CONMED’s President and Chief Executive Officer. "Our net sales performance on an organic constant currency basis reflected year-over-year growth across both our Orthopedic Surgery and General Surgery product lines, as our team continued to advance our key growth platforms: AirSeal, Buffalo Filter, and BioBrace. In tandem, we made meaningful progress on several strategic priorities during the quarter, including: completing the strategic exits of our gastroenterology product offerings in keeping with our portfolio optimization strategy, refinancing a portion of our debt, and further strengthening our leadership with key appointments to our Board and executive team." Mr. Beyer continued: "We are updating our financial guidance for the full year 2026 today to reflect both our second quarter performance and our updated outlook for the balance of the year. Looking ahead, our team remains focused on disciplined execution as we continue to position CONMED for quality, long-term growth and value creation." 2026 Financial Guidance The Company is updating its full year 2026 financial guidance to reflect its second quarter performance and updated outlook for the second half of 2026. For the twelve months ended December 31, 2026, the Company now expects: Notes to Financial Information Above (1) All growth rates are presented on a year-over-year basis, unless noted otherwise. (2) Constant currency growth, organic growth, organic constant currency growth, and adjusted EPS are non-GAAP financial measures. Reconciliations of GAAP to non-GAAP financial measures appear below. (3) Organic constant currency revenue excludes the sales of gastroenterology ("GI") product offerings for the three and six months ended June 30, 2026 and 2025, and twelve months ending December 31, 2026 and 2025, related to the Company’s previously announced strategic exits as part of its portfolio optimization strategy. (4) Information reconciling forward-looking adjusted diluted net earnings per share to the comparable GAAP financial measures is unavailable to the company without unreasonable effort, as discussed below. (5) "Prior financial guidance" reflects the Company’s full year 2026 financial guidance, previously updated on April 29, 2026. Conference Call The Company’s management will host a conference call today at 4:30 p.m. ET to discuss its second quarter 2026 results. To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call webcast can also be accessed from the "Investors" section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com. Forward-Looking Statements This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. Supplemental Information - Reconciliation of GAAP to Non-GAAP Financial Measures The Company supplements the reporting of its financial information determined under generally accepted accounting principles in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; organic sales growth; organic constant currency sales growth; adjusted gross profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted research and development expense; adjusted operating income; adjusted interest expense; adjusted other (income)/expense; adjusted income tax expense; adjusted effective income tax rate; adjusted net income and adjusted diluted net earnings per share (EPS). The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding its financial results and assessing its prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of its operations because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline for analyzing trends in the Company’s underlying business. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Management uses these non-GAAP financial measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process and bases certain management incentive compensation on these non-GAAP financial measures. Net sales on a constant currency basis, organic basis, and organic constant currency basis are non-GAAP measures. The Company analyzes net sales on a constant currency basis, organic basis, and organic constant currency basis to better measure the comparability of results between periods. Organic revenue excludes the sales of GI product offerings and organic constant currency revenue presents sales in constant currency and excludes the sales of GI product offerings. To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales. To measure earnings performance on a consistent and comparable basis, the Company excludes certain items that affect the comparability of operating results and the trend of earnings. These adjustments are irregular in timing, may not be indicative of past and future performance and are therefore excluded to allow investors to better understand underlying operating trends. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, cost of sales, selling and administrative expenses, research and development expense, operating income, interest expense, other (income)/expense, income tax expense, effective income tax rate, net income and diluted net earnings per share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures above, provide a more complete understanding of the business. The Company strongly encourages investors and shareholders to review its financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. We are unable to present a quantitative reconciliation of our expected diluted net earnings per share to expected adjusted diluted net earnings per share as we are unable to predict with reasonable certainty and without unreasonable effort the impact and timing of acquisition, integration and other charges. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our consolidated condensed statements of income. View source version on businesswire.com: https://www.businesswire.com/news/home/20260729028546/en/ Contacts CONMED Corporation Investor Relations [email protected]

LARGO, Fla., July 02, 2026--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website: https://www.conmed.com/en/investor-relations. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com. Forward-Looking Statements This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. View source version on businesswire.com: https://www.businesswire.com/news/home/20260702521474/en/ Contacts CONMED Corporation Dalton Henry Investor Relations Analyst [email protected]